John Haretos, MD
Geriatric Medicine · Pittsburgh, PANPI 1114087160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,648 and has fallen 55.7% since, to $1,174 in 2025. Among geriatric medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Johnson & Johnson$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- Pfizer$952
- Astellas Pharma US Inc$458
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,673100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $1,494 |
| Johnson & Johnson | 33 | $1,449 |
| Lilly USA, LLC | 80 | $1,301 |
| AbbVie(2 entities) | 61 | $1,199 |
| Pfizer | 43 | $952 |
| Astellas Pharma US Inc | 18 | $458 |
| Kowa Pharmaceuticals America, Inc. | 16 | $237 |
| Abbott | 10 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $139 |
| Amneal Pharmaceuticals LLC | 5 | $134 |
| AstraZeneca | 2 | $133 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
| Novartis | 2 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $115 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Arbor Pharmaceuticals, Inc. | 5 | $96 |
| Genentech USA, Inc. | 5 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Azurity Pharmaceuticals, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| GSK | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,678 in reported general payments places this provider in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tasimelteon | 12 | $244,280 |
| MounjaroTirzepatide | 40 | $51,325 |
| EliquisApixaban | 28 | $37,837 |
| JardianceEmpagliflozin | 34 | $36,208 |
| OzempicSemaglutide | 21 | $31,851 |
| XareltoRivaroxaban | 14 | $8,160 |
| Sucralfate | 11 | $4,936 |
| SynthroidLevothyroxine Sodium | 48 | $3,717 |
| Atorvastatin Calcium | 218 | $3,418 |
| EdarbiAzilsartan Medoxomil | 11 | $3,047 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,031 |
| PaxlovidNirmatrelvir/Ritonavir | 20 | $2,858 |
| Levothyroxine Sodium | 140 | $2,273 |
| Colchicine | 14 | $1,795 |
| Losartan Potassium | 148 | $1,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,301 | $51,32540 claims |
| PfizerEliquis, Paxlovid | $952 | $40,69548 claims |
| Boehringer IngelheimJardiance | $34 | $36,20834 claims |
| Novo NordiskOzempic | $1,494 | $31,85121 claims |
| Johnson & JohnsonXarelto | $1,449 | $8,16014 claims |
| AbbVieSynthroid | $1,199 | $3,71748 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $96 | $3,04711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $134 | $2,273140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in Pittsburgh
- Adele TowersPittsburgh$29K
- Debra WeinerPittsburgh$8K
- Namita YendePittsburgh$1K
- Umesh GolaniPittsburgh$622
- Bernard BernackiPittsburgh$498
- Richard StefanacciPhiladelphia$146K
- James LinErie$73K
- Michele ZaworaPhiladelphia$21K
- Daniel HaimowitzLevittown$15K
- Robert PearlsteinPlymouth Meeting$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.